Skip to content
Search

Latest Stories

Boots welcomes job applications from LloydsPharmacy staff

Boots has welcomed job applications from LloydsPharmacy staff impacted by the news of closure of all its branches located in Sainsbury’s before the end of 2023.

The company is recruiting for more than 1,500 pharmacy roles nationwide. Vacancies span pharmacy roles at all levels – from Pharmacy Advisors (Dispensers) and Trainee Pharmacists to experienced Pharmacists looking to develop their careers.


Sebastian James, Managing Director of Boots UK & ROI, said: “Pharmacies deliver vital healthcare in the heart of communities. News of the closure of LloydsPharmacy branches within Sainsbury’s stores will no doubt have an impact on many talented pharmacists as well as their patients.

“We have many roles available at Boots and welcome applications from LloydsPharmacy employees affected by the closures. Patients who are worried about their future pharmacy provision can check our store locator online to find out where their nearest Boots store is – our pharmacy team members are ready to help.”

There are over 2,200 Boots stores across the UK and 85% of the population live within 10 minutes of a Boots store.

In addition to a competitive salary and discretionary bonus scheme, Boots provides a comprehensive range of benefits to team members. These include access to the Boots Retirement Savings Plan pension scheme, a generous staff discount with enhanced savings on Boots own brand products and services and enhanced maternity, paternity and adoption leave pay.

Boots also offers a range of professional development opportunities in clinical services, including the chance to become one of over 2,200 Macmillan Information Pharmacists or progressing into store management. Earlier this year, Boots announced it would fund training bursaries for pharmacists who want to complete training to become pharmacist independent prescribers. To apply for one of the available pharmacy roles, visit boots.jobs/pharmacy.

More For You

How much did Uniphar grow in 2024?

2024 was an outstanding year for Uniphar

gettyimages

Uniphar reports strong 2024 growth, aims to double EBITDA by 2028

Uniphar, an international diversified healthcare services business, delivered a strong performance in 2024, achieving 9.6% growth in gross profit.

This growth resulted in a 6.4% rise in EBITDA, reaching €123.5 million (£102.4m) up from €116.0 million (£96.2m)the previous year.

Keep ReadingShow less
India Cracks Down on Unapproved Tapentadol-Carisoprodol Drug Exports

Tapentadol and carisoprodol combinations are potentially dangerous drugs

gettyimages

India bans export of unapproved tapentadol-carisoprodol drugs

The Union Health Ministry has taken immediate actionagainst a Mumbai-based pharmaceutical manufacturerfollowing reports of unapproved drug combinations containing Tapentadol and Carisoprodol being exported to certain West African countries.

Although Tapentadol and Carisoprodol are individually approved by Central Drugs Standard Control Organization (CDSCO) in India, their combination has not yet received approval.

Keep ReadingShow less
Infant formula: Food, diet and obesity committee welcomes CMA proposals, demands action on processed foods
CMA study shows that parents could save around £300 a year by switching to a lower priced infant formula brand (gettyimages)

Infant formula: CMA calls for stronger labelling and advertising rules

All infant formula brands should be displayed together and separately from other formula milks in stores to enable quick and easy price comparisons – suggests CMA 

The Competition and Marketing Authority (CMA) has recommended the governments of the four UK nations to strengthen advertising and labelling rules of infant formula to help parents make informed decisions and save money.

This follows a CMA study on infant formula and follow-on milks, which found that a combination of factors was leading to poor outcomes for parents.

Keep ReadingShow less
CPCF negotiations: CPE working to secure the best outcomes for the sector
Pharmacy sector demands urgent resolution of CPCF negotiations (gettyimages)

CPCF Negotiations: CPE unable to share details until official announcement

Acknowledging the sector's urgent need to resolve CPCF negotiations, CPE reiterates its commitment to securing the best possible outcome

Community Pharmacy England (CPE) has provided an update on the ongoing 2024/25 and 2025/26 Community Pharmacy Contractual Framework (CPCF) negotiations with the Department of Health and Social Care (DHSC) and NHS England.

“The Negotiating Team are continuing in-depth negotiations with DHSC and NHS England,” the Committee said, adding that they are focused on securing the “best outcomes” for pharmacy owners.

Keep ReadingShow less
David Thomas Steps In as NPA’s New Wales Representative
Five NPA members are contesting for the remaining position in England (gettyimages)

NPA board update: David Thomas succeeds Raj Aggarwal OBE

Five NPA members are contesting for the remaining position in England

David Thomas, owner of LT Chemists in Newport, will replace Raj Aggarwal OBE as the next National Pharmacy Association (NPA) board member for Wales, following an uncontested election this month.

Following the conclusion of a nomination process last week, Baldev Bange, Aisling O’Brien, Sehar Shahid, and Sanjay Ganvir have been re-elected to the Board, representing areas of England and Scotland, according to a statement from NPA.

Keep ReadingShow less